Patents by Inventor Tian-Lu Cheng
Tian-Lu Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11369690Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.Type: GrantFiled: August 24, 2018Date of Patent: June 28, 2022Assignee: ACADEMIA SINICA & KAOHSIUNG MEDICAL UNIVERSITYInventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
-
Patent number: 11135206Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.Type: GrantFiled: May 26, 2016Date of Patent: October 5, 2021Assignee: KAOHSIUNG MEDICAL UNIVERSITYInventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
-
Publication number: 20210292438Abstract: A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also disclosed is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. Further disclosed is a method for diagnosing a cell-mediated disorder by administering a PEG engager followed by a PEGylated diagnostic agent.Type: ApplicationFiled: June 7, 2021Publication date: September 23, 2021Applicant: ACADEMIA SINICAInventors: Steve ROFFLER, Tian-Lu Cheng, Yu-Cheng Su, Kuo-Hsiang Chuang
-
Patent number: 11052072Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.Type: GrantFiled: December 12, 2019Date of Patent: July 6, 2021Assignee: KAOHSIUNG MEDICAL UNIVERSITYInventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
-
Patent number: 11040111Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.Type: GrantFiled: August 24, 2018Date of Patent: June 22, 2021Assignees: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITYInventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
-
Publication number: 20210154319Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.Type: ApplicationFiled: August 24, 2018Publication date: May 27, 2021Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITYInventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
-
Publication number: 20200140572Abstract: A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also provided is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. A kit that contains a PEG engager and a PEGylated anti-cancer agent is also disclosed. Further disclosed are methods for imaging cells and diagnosing cancer by administering a PEG engager followed by a PEGylated imaging agent. Another kit is provided that includes the PEG engager and the PEGylated imaging agent.Type: ApplicationFiled: May 9, 2018Publication date: May 7, 2020Applicants: KAOHSIUNG MEDICAL UNIVERSITY, ACADEMIA SINICAInventors: Steve ROFFLER, Tian-Lu Cheng, Yu-Cheng Su, Kuo-Hsiang Chuang
-
Patent number: 10633453Abstract: Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.Type: GrantFiled: May 28, 2014Date of Patent: April 28, 2020Assignees: KAOHSIUNG MEDICAL UNIVERSITY, DCB-USA LLCInventors: Tian-Lu Cheng, Chih-Hung Chuang, Hsiu-Fen Ko, Yun-Chi Lu
-
Publication number: 20200113878Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.Type: ApplicationFiled: December 12, 2019Publication date: April 16, 2020Inventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
-
Publication number: 20200061205Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.Type: ApplicationFiled: August 24, 2018Publication date: February 27, 2020Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITYInventors: STEVEN R. ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, KUO-HSIANG CHUANG
-
Patent number: 10188742Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.Type: GrantFiled: March 2, 2015Date of Patent: January 29, 2019Assignee: KAOHSIUNG MEDICAL UNIVERSITYInventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
-
Publication number: 20190022245Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.Type: ApplicationFiled: August 24, 2018Publication date: January 24, 2019Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITYInventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
-
Patent number: 10180433Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.Type: GrantFiled: August 23, 2016Date of Patent: January 15, 2019Assignee: KAOHSIUNG MEDICAL UNIVERSITYInventors: Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
-
Publication number: 20180214426Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.Type: ApplicationFiled: May 26, 2016Publication date: August 2, 2018Inventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
-
Publication number: 20170056523Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.Type: ApplicationFiled: March 2, 2015Publication date: March 2, 2017Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITYInventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
-
Publication number: 20160356784Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.Type: ApplicationFiled: August 23, 2016Publication date: December 8, 2016Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: TIAN-LU CHENG, Steve ROFFLER, WEN-WEI LIN, I-JU CHEN
-
Patent number: 9458243Abstract: A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species.Type: GrantFiled: November 6, 2014Date of Patent: October 4, 2016Assignee: Kaohsiung Medical UniversityInventors: Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
-
Publication number: 20160185875Abstract: Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.Type: ApplicationFiled: May 28, 2014Publication date: June 30, 2016Applicant: DCB-USA LLCInventors: Tian-Lu Cheng, Chih-Hung Chuang, Hsiu-Fen Ko, Yun-Chi Lu
-
Patent number: 9329180Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.Type: GrantFiled: October 18, 2013Date of Patent: May 3, 2016Assignee: KAOHSIUNG MEDICAL UNIVERSITYInventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
-
Patent number: 9315815Abstract: The invention provides a method of high-throughput sorting of high expression protein-producing cell, which utilizes linking a protein and a transmembrane domain with a self-processing cleavage site and regulating the secretion of the protein or expression of protein on the cell membrane by adding self-processing cleavage enzyme inhibitor. Then, the high expression cell line can be high-throughput sorted by a detection technique. The invention also provides a recombinant nucleotide sequence and a vector used in the method and a cell sorted by the method.Type: GrantFiled: April 28, 2014Date of Patent: April 19, 2016Assignee: Taipei Medical UniversityInventors: Kuo-Hsiang Chuang, Tian-Lu Cheng, I-Shiuan Chiang, Yuan-Chin Hsieh